Wednesday, January 21, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Analysis

Nel ASA Faces Severe Headwinds as Order Intake Plummets

Robert Sasse by Robert Sasse
October 21, 2025
in Analysis, Earnings, European Markets, Hydrogen, Turnaround
0
Nel ASA Stock
0
SHARES
20
VIEWS
Share on FacebookShare on Twitter

The hydrogen sector specialist Nel ASA is confronting substantial operational challenges, with recent quarterly results revealing significant deterioration across key performance metrics. The company’s latest financial disclosures paint a concerning picture for the electrolyzer manufacturer’s near-term prospects.

Financial Performance Shows Marked Decline

During the second quarter of 2025, Nel ASA reported revenues of just 174 million Norwegian Kronen, representing a stark 48 percent decline compared to the same period last year. The company’s operational losses widened slightly, with EBITDA standing at negative 86 million NOK. These figures underscore the substantial operational headwinds the company currently faces, highlighting the gap between the renewable energy sector’s long-term potential and immediate implementation challenges.

Order Collapse Reaches Critical Levels

The most alarming development emerges from the company’s order pipeline. New order intake collapsed by 74 percent year-over-year to a mere 71 million Norwegian Kronen. The order backlog, a crucial indicator of future revenue potential, contracted significantly by 40 percent to 1,249 million Kronen.

This downturn was particularly severe within the alkaline electrolyzer segment, where orders plummeted by 94 percent. While the PEM segment demonstrated relative stability, it proved insufficient to counterbalance the overwhelming decline across the business. This pattern suggests deep-seated market uncertainty and hesitation among potential clients.

Should investors sell immediately? Or is it worth buying Nel ASA?

Industry-Wide Pressures Intensify

Nel ASA’s struggles occur against a backdrop of sector-wide difficulties. The entire hydrogen industry is experiencing protracted delays in final investment decisions for major projects. This widespread investment caution represents a primary driver behind the deteriorating order figures.

The company suffered an additional setback with energy firm Statkraft canceling a significant 40-megawatt electrolyzer contract. Market conditions currently present little room for optimistic interpretation, as demonstrated by these key metrics:

  • Q2 2025 Revenue: 48% year-over-year decrease
  • Q2 2025 Order Intake: 74% year-over-year decline
  • Order Backlog: 40% year-over-year reduction
  • Q2 2025 EBITDA: Negative 86 million NOK

Despite these challenging conditions, a recent order from H2 Energy in early October provided a minor positive development. However, this single contract does little to alter the prevailing negative trajectory. The company’s performance continues to reflect a clear downward trend, with recovery prospects remaining uncertain amid current market dynamics.

Ad

Nel ASA Stock: Buy or Sell?! New Nel ASA Analysis from January 21 delivers the answer:

The latest Nel ASA figures speak for themselves: Urgent action needed for Nel ASA investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from January 21.

Nel ASA: Buy or sell? Read more here...

Tags: Nel ASA
Robert Sasse

Robert Sasse

About Dr. Robert Sasse Accomplished economist, entrepreneur, and profound expert in financial markets. Dr. Robert Sasse holds a doctorate in economics and combines academic rigor with practical entrepreneurial experience. His deep expertise in economic relationships and unwavering conviction for a free-market liberal economic order drives his mission to provide investors with well-founded knowledge and guidance.
Areas of Expertise:
  • Economic Theory and Practice
  • Free-Market Economics
  • Entrepreneurship and Business Strategy
  • Investment Philosophy
Dr. Sasse's unique combination of academic knowledge and real-world business experience enables him to provide investors with comprehensive insights that bridge theory and practice.

Related Posts

Viking Therapeutics Stock
Analysis

Viking Therapeutics Stock Gains Momentum on Promising Clinical Data

January 21, 2026
Metaplanet Stock
Analysis

Metaplanet Shares Experience Pullback Following Significant Rally

January 21, 2026
Micron Stock
AI & Quantum Computing

Micron’s Valuation Faces Scrutiny Amid AI-Driven Surge

January 21, 2026
Next Post
Vulcan Energy Resources Stock

Strategic Partnership with Glencore Marks Turning Point for Vulcan Energy

Infineon Stock

Infineon Shares: The Struggle for Market Momentum

Commerzbank Stock

Commerzbank Unleashes Billion-Euro Share Buyback Program

Recommended

CureVac Stock

CureVac Shareholders Approve Landmark BioNTech Acquisition

2 months ago

Yum Brands Faces Disappointment with Q4 Earnings

2 years ago
Intel Stock

Intel Faces Leadership Challenge as Top AI Executive Departs for OpenAI

2 months ago
D-Wave Quantum Stock

D-Wave Quantum Shares Face Mounting Pressure

2 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics Wolfspeed
No Result
View All Result

Highlights

AMD’s AI Ambitions Face Scrutiny Amid Record Share Performance

Alphabet Shares Navigate Volatility with Underlying Strength

Strategy Shares Tumble Following Major Equity Offering

Eos Energy Unveils Next-Generation Storage Platform Amid Leadership Transition

XRP’s Diverging Path: Network Activity Soars as Price Struggles

Can Sangamo Therapeutics Reach Profitability by 2027?

Trending

Viking Therapeutics Stock
Analysis

Viking Therapeutics Stock Gains Momentum on Promising Clinical Data

by Felix Baarz
January 21, 2026
0

Shares of Viking Therapeutics experienced a significant rally in today's trading session, marking a notable recovery after...

Metaplanet Stock

Metaplanet Shares Experience Pullback Following Significant Rally

January 21, 2026
Micron Stock

Micron’s Valuation Faces Scrutiny Amid AI-Driven Surge

January 21, 2026
AMD Stock

AMD’s AI Ambitions Face Scrutiny Amid Record Share Performance

January 21, 2026
Alphabet Stock

Alphabet Shares Navigate Volatility with Underlying Strength

January 20, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Viking Therapeutics Stock Gains Momentum on Promising Clinical Data
  • Metaplanet Shares Experience Pullback Following Significant Rally
  • Micron’s Valuation Faces Scrutiny Amid AI-Driven Surge

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com